Tuesday, October 06, 2020 10:59:35 AM
Dumb question alert from a newbie. Is it possible that they are waiting to sign off on the POR at the 30 day mark (10 Sept) so they can drop the “Q” at the same time as they approve the POR. Or does the 30 days start after the effective POR date?
Recent BRTX News
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 05/07/2026 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:17:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/30/2026 08:10:19 PM
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform • GlobeNewswire Inc. • 04/30/2026 02:36:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/29/2026 04:15:14 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/27/2026 08:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 09:12:57 PM
- BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform • GlobeNewswire Inc. • 04/21/2026 12:00:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/20/2026 09:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:22:23 PM
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform • GlobeNewswire Inc. • 04/07/2026 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 06:46:20 PM
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:20:29 PM
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform • IH Market News • 02/24/2026 03:14:07 PM
- BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 09:12:24 PM
- BioRestorative Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/14/2026 01:30:00 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/13/2026 02:48:15 PM
